Trial Profile
A Phase IIA, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Immunogenicity Trial of AAB-001 in Patients With Mild to Moderate AD
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 17 Jan 2017
Price :
$35
*
At a glance
- Drugs Bapineuzumab (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- 17 Jan 2017 New trial record